Skip to Content
Merck
  • ADAR1 function affects HPV replication and is associated to recurrent human papillomavirus-induced dysplasia in HIV coinfected individuals.

ADAR1 function affects HPV replication and is associated to recurrent human papillomavirus-induced dysplasia in HIV coinfected individuals.

Scientific reports (2019-12-29)
Maria Pujantell, Roger Badia, Iván Galván-Femenía, Edurne Garcia-Vidal, Rafael de Cid, Carmen Alcalde, Antonio Tarrats, Marta Piñol, Francesc Garcia, Ana M Chamorro, Boris Revollo, Sebastian Videla, David Parés, Javier Corral, Cristina Tural, Guillem Sirera, José A Esté, Ester Ballana, Eva Riveira-Muñoz
ABSTRACT

Infection by human papillomavirus (HPV) alters the microenvironment of keratinocytes as a mechanism to evade the immune system. A-to-I editing by ADAR1 has been reported to regulate innate immunity in response to viral infections. Here, we evaluated the role of ADAR1 in HPV infection in vitro and in vivo. Innate immune activation was characterized in human keratinocyte cell lines constitutively infected or not with HPV. ADAR1 knockdown induced an innate immune response through enhanced expression of RIG-I-like receptors (RLR) signaling cascade, over-production of type-I IFNs and pro-inflammatory cytokines. ADAR1 knockdown enhanced expression of HPV proteins, a process dependent on innate immune function as no A-to-I editing could be identified in HPV transcripts. A genetic association study was performed in a cohort of HPV/HIV infected individuals followed for a median of 6 years (range 0.1-24). We identified the low frequency haplotype AACCAT significantly associated with recurrent HPV dysplasia, suggesting a role of ADAR1 in the outcome of HPV infection in HIV+ individuals. In summary, our results suggest that ADAR1-mediated innate immune activation may influence HPV disease outcome, therefore indicating that modification of innate immune effectors regulated by ADAR1 could be a therapeutic strategy against HPV infection.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting human DDX58
Sigma-Aldrich
MISSION® esiRNA, targeting human ADAR
illustra ExoProStar, Cytiva US78210, sufficient for 100 reactions
Sigma-Aldrich
MISSION® esiRNA, targeting human IFIH1